How much funding has Orchard Therapeutics raised?

Orchard Therapeutics has raised $293.0M in total funding, most recently a Series C round.

Who are Orchard Therapeutics's investors?

Orchard Therapeutics's investors include F-Prime Capital, RA Capital Management.

When was Orchard Therapeutics founded?

Orchard Therapeutics was founded in 2015.

Where is Orchard Therapeutics headquartered?

Orchard Therapeutics is headquartered in London, United Kingdom.

What industry is Orchard Therapeutics in?

Orchard Therapeutics operates in Biotech.

How many employees does Orchard Therapeutics have?

Orchard Therapeutics has 51-200 employees.

Orchard Therapeutics

IPO

Homepage

London, United Kingdom · Founded 2015 · $293.0M raised

Biotech

Headquarters: London
Employees: 51–200
Founded: 2015
Business Model: B2B

Website: orchard-tx.com
Total Funding: $293.0M
Last Round: $150.0M Series CAug 2018
Rounds: 3

About

Founded in 2015, Orchard Therapeutics is a London-based gene therapy company and a Kyowa Kirin subsidiary since 2024, focused on ex vivo autologous hematopoietic stem cell (HSC) gene therapies for severe rare genetic diseases. The company's lead product Lenmeldy (atidarsagene autotemcel) received FDA approval for metachromatic leukodystrophy and is also approved in Europe as Libmeldy. Orchard has approximately 193 employees.

Summary

Orchard Therapeutics is a Biotech company based in London, United Kingdom, founded in 2015. It has raised $293.0M in total across 3 rounds, most recently a $150.0M Series C round in Aug 2018. Investors include F-Prime Capital and RA Capital Management.

LinkedIn X (Twitter)